Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion type Assertion NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_head.
- NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion description "[Collectively, these data suggest that ABHD6 inhibitors may serve as therapeutics for obesity, nonalcoholic fatty liver disease, and type II diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_provenance.
- NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion evidence source_evidence_literature NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_provenance.
- NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion SIO_000772 24095738 NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_provenance.
- NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion wasDerivedFrom befree-2016 NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_provenance.
- NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_assertion wasGeneratedBy ECO_0000203 NP1116294.RAXl4swnJA5ChwzS7WmmyyOm_tSKlEfbfxZFECP_LwXzA130_provenance.